Table 4.

Risk of development of dnDSA

VariableMultivariate Analysis
HR (95% CI)P Value
Induction group
 Anti-thymocyte globulin1
 Alemtuzumab4.2 (1.57 to 11.04)0.004
 Basiliximab1.2 (0.67 to 2.26)0.50
Race
 White1
 Black2.4 (1.42 to 4.02)0.001
 Other1.6 (0.89 to 3.02)0.12
Donor type
 Live1
 DBD0.9 (0.53 to 1.58)0.75
 DCD1.7 (0.95 to 3.02)0.07
Age at transplant (yr)0.98 (0.96 to 0.99)0.01
End cPRA1.0 (0.99 to 1.01)0.94
Transplant to discharge (d)1.1 (1.00 to 1.14)0.05
Maintenance steroids1.7 (0.59 to 4.59)0.34
Belatacept1.6 (0.61 to 4.19)0.34
  • dnDSA, de novo donor-specific antibody; HR, hazard ratio; DBD, donation by brainstem death; DCD, donation by cardiac death; cPRA, calculated panel-reactive antibody.